DNDi E-news
June 2016  |   View Online

The global response to AMR must not fail to address the needs of neglected patients


Viewpoint by Manica Balasegaram, Director, Global Antibiotic Research and Development Partnership

Far from being an apocalyptic fantasy, a post-antibiotic era in which common infections and minor injuries can kill has become a very real possibility. Of late, media headlines about ‘the end of the road’ for antibiotics have been plentiful. The latest case in May this year to receive a good deal of attention was of a patient in the US found to be carrying bacteria resistant to antibiotics of last resort. »

Mycetoma added to WHO List of ‘Neglected Tropical Diseases’

On 28 May 2016, the 69th World Health Assembly approved a Resolution that officially recognizes mycetoma as a neglected tropical disease. Including mycetoma on the WHO list of neglected tropical diseases will give the disease the political standing that it needs. Donors will now consider supporting the disease, and global mycetoma programmes will be established, allowing for a better understanding of the epidemiology, early diagnosis, risk factors, and treatment strategies. »

MULTIMEDIA: Learn about the devastation caused by mycetoma and the work done by the Mycetoma Research Centre to support neglected patients in Sudan. »

DNDi's new global antibiotic research and development partnership garners seed funding and political support

With commitments from MSF and four governments (Germany, South Africa, the United Kingdom, and the Netherlands), the Global Antibiotic Research and Development Partnership, a new joint initiative by WHO and DNDi to develop new antibiotic treatments to address antimicrobial resistance announced that it has the necessary funding and political support to build its strategy, initial R&D portfolio, and start-up team. »  

Mundo Sano, Chemo & DNDi join forces to register benznidazole

Less than 1% of the 7 million people affected with Chagas disease have access to treatment. DNDi, civil society organization Mundo Sano, and pharmaceutical company Chemo Group, unveiled a new partnership to address this shocking lack of access, by registering benznidazole, an essential medicine to treat the disease, in the US and across Latin America. »

Celgene joins DNDi’s “Drug Discovery Booster” consortium

Celgene has become the fifth company and first US-based biopharmaceutical partner to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, an initiative established to accelerate and cut the cost of early-stage drug discovery for leishmaniasis and Chagas disease. The Drug Discovery Booster uses a new approach, using a multilateral, simultaneous search process across participating companies, cutting years off drug development timelines. »

DNDi Innovation and Access:
Partners’ Meeting 2016

More than 100 participants from the field of R&D for neglected diseases, including international scientists, product developers, policy-makers, and civil society organizations, took part in a series of events - the DNDi Partners’ Meeting, and Meetings & Workshops of the Chagas Platform and the redeLEISH Network - in order to promote the best science for the most neglected.
See the full programme and presentations »

At the meeting, DNDi recognized the work of Latin American partners for NTD research. Ruta N Medellín, an organization based in Medellin, Colombia, which focuses on knowledge as a primary source for research and development, was awarded the Innovative Funding Mechanism Award for its funding of leishmaniasis.

The Partnership of the Year Award was presented to LOLA, a Latin American Lead Optimization Programme. The LOLA project uses an international collaborative approach, working with UNICAMP (University of Campinas) with partners in the USA (AbbVie) and Europe (LMPH, University of Antwerp, Belgium) to carry out early stage drug discovery and sets a precedent for all emerging neglected disease endemic countries. »  

Scientific Articles

Transactions of the Royal Society of Tropical Medicine and Hygiene
The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis. »

Clinical Microbiology and Infection
IL-2 as a marker for detecting asymptomatic individuals in areas where Leishmania infantum is endemic. »
Photo credits:
Fábio Nascimento DNDi/Abraham Ali
Punto de Vista: Manica Balasegeram »
DNDi, Mundo Sano y Chemo se unen para registrar benznidazol »

Ponto de Vista: Manica Balasegeram »
DNDi, Mundo Sano e Chemo se unem para registrar benznidazol »
Chagas Platform
redeLEISH Network
HAT Platform


AIDS 2016
Scale up HIV treatment for children: The right tools, right now!

Durban, 21 July 2016
HIV treatment for adults has been revolutionized since the landmark AIDS Conference in 2000, but children remain neglected. DNDi is co-hosting a satellite session on the development of optimal paediatric formulations.
Toledo, 16-20 May 2017
Registration and abstract submission for World Leish-6 is opening soon. The WorldLeish-6 Scientific Community and PLOS Collections call for research papers for a special PLOS WorldLeish-6 Collection, and DNDi will award prizes to 20 researchers.


ISNTD d3 2016
London, 25-26 May 2016

GHTC Panel Discussion
Geneva, 23 May 2016
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2016 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book